Earnings Insights
AI-generated analysis of quarterly earnings, concall highlights, and financial performance across Indian listed companies.
How to use these insights
Each article is built from earnings call transcripts and structured rank signals. Start with the latest summary, then open the stock page for the full company view, the concall page for quarter-by-quarter commentary, and the rankings dashboard to compare peers.
Valiant Organics Q3 FY26 earnings call: Revenue & Margins | Arthneeti
Q3 FY26
Q3-FY26 Consolidated Revenue from Operations: INR 1,593 Mn, down 14.8% YoY (Q3-FY25: INR 1,869 Mn) . Key concall takeaways from Valiant Organics Ltd's Q3 FY26…
24 Sept 2026
Valiant Organics Q4 FY26 earnings call: Revenue & Margins | Arthneeti
Q4 FY26
Q4-FY26 Consolidated Revenue from Operations: INR 2,178 million, up 6.9% year-on-year from INR 2,038 million in Q4-FY25 (Page 12). Key concall takeaways from…
24 Sept 2026
Valiant Organics Q1 FY27 earnings call: Revenue & Margins | Arthneeti
Q1 FY27
Year-on-year (YoY) growth in Revenue: 13.3% increase from INR 2,044 million in Q1-FY26 (Page 13, 12) . Key concall takeaways from Valiant Organics Ltd's Q1…
24 Sept 2026
Sacheerome Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
Reported annual revenues for FY25: ₹10,753.59 lakhs, up from ₹8,509.53 lakhs in FY24 (26.4% YoY growth) and ₹7,049.19 lakhs in FY23. Key concall takeaways from…
24 Sept 2026
Sacheerome Q1 FY27 earnings call: Revenue & Margins | Arthneeti
Q1 FY27
For H2 FY26, total income was ₹7,806.30 Lakhs, up 35.57% from ₹5,758.16 Lakhs in H2 FY25 (Page 20). Key concall takeaways from Sacheerome Ltd's Q1 FY27…
24 Sept 2026
Excel Industries Q3 FY24: Revenue ₹180.3 Cr, PAT ₹2.8 Cr | Arthneeti
Q3 FY24
Q3 FY24 revenue: ₹180.3 crore, down 19.1% year-on-year (Page 9 & 8) . Key concall takeaways from Excel Industries Ltd's Q3 FY24 earnings call — and how it…
24 Sept 2026
Excel Industries Q4 FY24: Revenue ₹233.5 Cr, PAT ₹7.3 Cr | Arthneeti
Q4 FY24
Q4 FY24 revenue: ₹233.5 Cr, a 3.3% increase quarter-on-quarter and a 29.5% increase year-on-year (Page 11, 9, 7, 5). Key concall takeaways from Excel…
24 Sept 2026
Excel Industries Q1 FY25: Revenue ₹264.9 Cr, PAT ₹31.5 Cr | Arthneeti
Q1 FY25
Q1 FY25 Revenue from Operations: ₹264.9 crore, a 23.6% year-on-year (YoY) increase from ₹214.3 crore in Q1 FY24. Key concall takeaways from Excel Industries…
24 Sept 2026
Excel Industries Q2 FY25: Revenue ₹269 Cr, PAT ₹35.7 Cr | Arthneeti
Q2 FY25
Q2 FY25 standalone revenue from operations: ₹269 crore, up 1.51% QoQ from Q1 FY25 (₹265 crore). Key concall takeaways from Excel Industries Ltd's Q2 FY25…
24 Sept 2026
Excel Industries Q3 FY25: Revenue ₹196 Cr, PAT ₹6 Cr | Arthneeti
Q3 FY25
Q3 FY25 revenue: ₹196 crore, a 27% decline from Q2 FY25 (Page 5, 6). Key concall takeaways from Excel Industries Ltd's Q3 FY25 earnings call — and how it ranks…
24 Sept 2026
Excel Industries Q1 FY27: Revenue ₹293.7 Cr, PAT ₹29.1 Cr | Arthneeti
Q1 FY27
Q1 FY27 revenue from operations (standalone) was ₹293.7 Cr, down 5.1% YoY from ₹309.5 Cr in Q1 FY26 (Pages 8, 10). Key concall takeaways from Excel Industries…
24 Sept 2026
Excel Industries Q1 FY26: Revenue ₹309.5 Cr, PAT ₹33.5 Cr | Arthneeti
Q1 FY26
Q1 FY26 revenue from operations: ₹309.5 crore, a 16.8% year-on-year increase compared to Q1 FY25 (₹264.9 crore). Key concall takeaways from Excel Industries…
24 Sept 2026
Excel Industries Q3 FY26: Revenue ₹233.5 Cr, PAT ₹8.4 Cr | Arthneeti
Q3 FY26
Q3 FY26 revenue: ₹233.5 Cr (Standalone and Consolidated), up 18.9-19% YoY from ₹196.4 Cr in Q3 FY25 (Pages 6, 8, 9) . Key concall takeaways from Excel…
24 Sept 2026
Lincoln Pharmaceuticals Q2 FY24: Revenue ₹6,435 Cr, PAT ₹317 Cr | Arthneeti
Q2 FY24
Revenue**: ₹6,435 crore, up 19% year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY24 earnings call — and how it ranks against sector…
24 Sept 2026
Lincoln Pharmaceuticals Q3 FY24 earnings call: Revenue & Margins | Arthneeti
Q3 FY24
EBITDA**: ₹1,150 crore, showing a year-on-year increase of 34%. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q3 FY24 earnings call — and how it…
24 Sept 2026
Lincoln Pharmaceuticals Q2 FY25 earnings call: Revenue & Margins | Arthneeti
Q2 FY25
EBITDA**: ₹1,234 crore, up 15% YoY . Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY25 earnings call — and how it ranks against sector peers.
24 Sept 2026
Lincoln Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins | Arthneeti
Q3 FY25
EBITDA:** ₹32.2 crore, up 16% year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q3 FY25 earnings call — and how it ranks against sector…
24 Sept 2026
Lincoln Pharmaceuticals Q4 FY25 earnings call: Revenue & Margins | Arthneeti
Q4 FY25
Revenue: $1.2 billion, representing a 5% increase year-on-year. Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q4 FY25 earnings call — and how it…
24 Sept 2026
Lincoln Pharmaceuticals Q1 FY26 earnings call: Revenue & Margins | Arthneeti
Q1 FY26
EBITDA for the quarter: ₹9.19 crore, up 52.3% year-on-year . Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks…
24 Sept 2026
Lincoln Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins | Arthneeti
Q2 FY26
EBITDA: ₹2,927 Crore, a YoY increase of 10.4% . Key concall takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY26 earnings call — and how it ranks against…
24 Sept 2026